surmount-osa trial tirzepatide results for the Treatment of Obstructive Sleep Apnea and Obesity π @NEJM π https://t.co/RKdvTJxd7Y #ADA2024 Effect of tirzepatide treatment on
Description
fenfluramine was subsequently withdrawn from the US market in fall of 1997
Tirzepatide, a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, follows a structured titration schedule with dose increases typically occurring every four weeks
Rated 5 out of 5 Dana H
Most people who persist through the initial adjustment periods achieve substantial weight loss that makes the temporary discomfort worthwhile
At 250 pounds starting weight, that means roughly 12 to 30 pounds lost
